Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir/ritonavir monotherapy

HIV Medicine

Volumn 16, Issue 1, 2015, Pages 57-61

  Torres Cornejo, A ^a   Benmarzouk Hidalgo, Oj ^a   Gutierrez Valencia, A ^a   Ruiz Valderas, R ^a   Viciana, P ^a   Lopez Cortes L F ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

HIV protease gene; HIV reservoir; HIV 1 therapy; Resistance mutation; Ritonavir boosted darunavir monotherapy

Indexed keywords

DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS RNA; PROTEINASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; SULFONAMIDE;

ADULT; ARTICLE; COHORT ANALYSIS; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PROTEASE GENE; MAJOR CLINICAL STUDY; MEASUREMENT; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS GENE; VIRUS REPLICATION; WILD TYPE; ANTIVIRAL RESISTANCE; DRUG EFFECTS; FEMALE; GENETICS; HIV INFECTIONS; MALE; MISSENSE MUTATION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DARUNAVIR; DRUG RESISTANCE, VIRAL; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; PROSPECTIVE STUDIES; RITONAVIR; SULFONAMIDES;

EID: 84916600896     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12170     Document Type: Article

References (17)

1. Arribas JR, Doroana M, Turner D, Vandekerckhove L, Streinu-Cercel A. Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting. AIDS Res Ther 2013; 10: 3-11.
2. Lambert-Niclot S, Flandre P, Valantin MA etal. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis 2011; 204: 1211-1216.
3. Doyle T, Geretti AM. Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis 2012; 25: 17-25.
4. Cohen Stuart JW, Wensing AM, Kovacs C etal. Transient relapses ('blips') of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr 2001; 28: 105-113.
5. Martinez-Picado J, DePasquale MP, Kartsonis N etal. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci U S A 2000; 97: 10948-10953.
6. Noe A, Plum J, Verhofstede C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother 2005; 55: 410-412.
7. Lambotte O, Chaix ML, Gubler B etal. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 2004; 18: 1147-1158.
8. Pulido F, Arribas JR, Hill A, Van Delft Y, Moecklinghoff C. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy. Antivir Ther 2011; 16: 59-65.
9. Lambert-Niclot S, Flandre P, Valantin MA etal. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy. J Antimicrob Chemother 2012; 67: 1470-1474.
10. Johnson VA, Brun-Vezinet F, Clotet B etal. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17: 138-145.
11. Torres-Cornejo A, BenMarzouk-Hidalgo OJ, Gutierrez-Valencia A etal. Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy. AIDS 2014; 28: 201-208.
12. Kabamba-Mukadi B, Duquenne A, Henrivaux P etal. HIV-1 proviral resistance mutations: usefulness in clinical practice. HIV Med 2010; 11: 483-492.
13. Usuku S, Noguchi Y, Sakamoto M etal. Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 RNA and PBMC HIV-1 DNA in the same patient. Jpn J Infect Dis 2006; 59: 122-125.
14. Wirden M, Soulie C, Valantin MA etal. Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. J Antimicrob Chemother 2011; 66: 709-712.
15. Palmisano L, Galluzzo CM, Giuliano M. The importance of testing genotypic resistance in proviral DNA of patients fully responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 51: 233-234.
16. De Meyer S, Azijn H, Surleraux D etal. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49: 2314-2321.
17. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Bethune MP, Schiffer CA. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004; 78: 12012-12021.